News | November 16, 2020

IGBA Launches First Global Biosimilars Week

Today the International Generic and Biosimilar Medicines Association (IGBA) launched the first ever Global Biosimilars Week, which is aimed at raising the awareness of biosimilar medicines worldwide through a globally aligned educational initiative.

IGBA Global Biosimilars Week will take place from November 16 to 20, and will be supported by a dedicated website that contains resources and information for everyone, from patients to doctors. Biosimilars benefits, regulation, clinical use and market adoption will be covered.

“There is a wealth of information available globally about biosimilar medicines and the real-world evidence supporting their safety, efficacy and use,” explained Hanan Sboul, Chair of the IGBA. “Enhanced knowledge of biosimilar medicines will support improved access to life-saving biological treatments and support healthcare systems, which are under increasing pressure due to the rising costs of innovative treatments and the new fiscal demands created by the Covid-19 global public health crisis.”

“With this awareness campaign, the IGBA is providing a one-stop solution for anyone wanting to know more about biosimilar medicines. We invite all stakeholders to get involved and engage in the conversation by following along on social media using the hashtag #GlobalBiosimilarsWeek,” said Erika Satterwhite, Chair of the IGBA Biosimilars Committee.

IGBA member companies are the pioneers and global leaders in the development and marketing of biosimilar medicines. To date there have been more than 300 biosimilar approvals in jurisdictions representative of the IGBA’s membership, covering more than 10 therapeutic areas including oncology, rheumatoid arthritis, psoriasis, inflammatory bowel disease, growth disorders, nephrology, fertility and diabetes.

About IGBA
The International Generic and Biosimilar medicines Association (IGBA) strengthens cooperation between associations representing manufacturers of generic and biosimilar medicines from around the world. The IGBA is at the forefront of preserving sustainable competition within our industry, by stimulating competitiveness and innovation in the pharmaceutical sector; thereby, ensuring millions of patients worldwide have access to high quality, pro-competitive medicines. For more information, visit

Source: The International Generic and Biosimilar medicines Association (IGBA)